Scheffel, Matthew J.
Scurti, Gina
Wyatt, Megan M. http://orcid.org/0000-0003-1316-260X
Garrett-Mayer, Elizabeth
Paulos, Chrystal M.
Nishimura, Michael I.
Voelkel-Johnson, Christina http://orcid.org/0000-0001-6909-6678
Funding for this research was provided by:
National Cancer Institute (P01 CA154778, P30 CA138313)
Article History
Received: 30 August 2017
Accepted: 22 January 2018
First Online: 2 February 2018
Compliance with ethical standards
:
: All authors declare that they have no conflict of interest.
: Apheresis and cells from melanoma patients were obtained as part of clinical trial that is registered with clinicaltrials.gov NCT01586403 and was approved by the Institutional Review Board at Loyola Medical University Center (LU 203732). All procedures performed in studies using human participants were in accordance with the ethical standards of the institutional and/or national research committee, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All animal experiments were performed with approval by the Institutional Animal Care and Use Committee at the Medical University of South Carolina to ensure that ethical regulatory and policy mandates governing the use of animals in research are met (Animal Welfare Assurance #A3428-01). All methods were performed in accordance with the relevant guidelines and regulations.
: Informed consent was obtained from all individual participants included in the study.
: TRP-1 TCR transgenic mice, originally obtained from Dr. Nicolas Restifo, were provided by Dr. Chrystal Paulos. Recipient C57BL6 mice were purchased from Jackson Laboratories.
: The tumor-cell lines in this study are used to determine T-cell reactivity and specificity, so the critical feature is their HLA and antigen expression. Cells are, therefore, routinely checked to ensure their antigen (tyrosinase) and expression HLA (HLA-A2 for MEL624) is correct.